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Glucocorticoids are highly conserved fundamental regulators of energy homeostasis. In
response to stress in the form of perceived danger or acute inflammation, glucocorticoids
are released from the adrenal gland, rapidly mobilizing energy from carbohydrate, fat
and protein stores. In the case of inflammation, mobilized protein is critical for the rapid
synthesis of acute phase reactants and an efficient immune response to infection. While
adaptive in response to infection, chronic mobilization can lead to a profound depletion
of energy stores. Skeletal muscle represents the major body store of protein, and can
become substantially atrophied under conditions of chronic inflammation. Glucocorticoids
elicit the atrophy of muscle by increasing the rate of protein degradation by the
ubiquitin-proteasome system and autophagy lysosome system. Protein synthesis is also
suppressed at the level of translational initiation, preventing the production of new
myofibrillar protein. Glucocorticoids also antagonize the action of anabolic regulators such
as insulin further exacerbating the loss of protein and muscle mass. The loss of muscle
mass in the context of chronic disease is a key feature of cachexia and contributes
substantially to morbidity and mortality. A growing body of evidence demonstrates
that glucocorticoid signaling is a common mediator of wasting, irrespective of the
underlying initiator or disease state. This review will highlight fundamental mechanisms
of glucocorticoid signaling and detail the mechanisms of glucocorticoid-induced muscle
atrophy. Additionally, the evidence for glucocorticoids as a driver of muscle wasting in
numerous disease states will be discussed. Given the burden of wasting diseases and
the nodal nature of glucocorticoid signaling, effective anti-glucocorticoid therapy would be
a valuable clinical tool. Therefore, the progress and potential pitfalls in the development of
glucocorticoid antagonists for muscle wasting will be discussed.
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INTRODUCTION
Energy balance in vertebrate animals is a highly regulated pro-
cess that is differentially modulated to respond to a diverse
array of challenges. Fundamentally, organisms must risk their
current energy stores to find food, avoid predation, fight infec-
tion, and to reproduce. Given the critical importance of energy
metabolism to organismal fitness, numerous evolutionary pres-
sures have acted on this process. One of the most profound
challenges tomammalian energy homeostasis is acute infection. A
multitude of behavioral and metabolic changes occur that greatly
tax energy reserves. The febrile response is a fundamental medi-
ator of innate immunity. It is estimated that a 13% increase in
metabolic rate is required for every 1◦ increase in body temper-
ature (Kluger, 1978). Simultaneously, the immune system must
become anabolic, producing granulocytes, antibodies and acute
phase proteins to combat the infection. This dramatic increase
in energy consumption comes in the face of the seemingly para-
doxical behavioral response of a decrease in appetite (Hart,
1988). There are a number of possible purposes to this behavior,
including a decreased risk of predation during this period and
the energetic cost of finding and digesting food (Exton, 1997).
Regardless of the evolved purpose, this leads to a marked imbal-
ance between energy intake and expenditure draws heavily on
energy stores, and in particular skeletal muscle (Baracos et al.,
1983).
Endogenous glucocorticoids are one of the most primitive
regulators of energy homeostasis. Named for their ability to
increase serum glucose, glucocorticoids have important roles
in modifying carbohydrate, fat and protein metabolism as well
as numerous other physiologic functions. Glucocorticoid recep-
tors (GR) are conserved down to teleosts where they play a
similar role in metabolism (Wendelaar Bonga, 1997). Cortisol,
the physiologic glucocorticoid in humans, is produced by the
zona fasiculata of the adrenal cortex in response to adrenocor-
ticotrophic hormone (ACTH) released by the anterior pituitary.
ACTH, in turn is regulated by the hypothalamic production
and release of corticotropin-releasing hormone forming the api-
cal component of the hypothalamic-pituitary-adrenal axis (HPA
axis). Numerous stressors activate the HPA axis, releasing cortisol
and mobilizing energy reserves. Skeletal muscle serves as a major
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body store of amino acids, and glucocorticoids act to induce
the catabolism of this tissue, increasing the plasma levels of free
amino acids (Wise et al., 1973). Under conditions of starvation,
HPA activation and subsequent proteolysis in skeletal muscle pro-
vides amino acid substrate for hepatic gluconenogenesis (Pilkis
et al., 1988). The HPA axis is also activated in response to inflam-
mation, with the released amino acids fueling the synthesis of
acute phase reactants (Figure 1) (Besedovsky et al., 1986).
While adaptive in the setting of starvation or acute infec-
tion, prolonged mobilization of muscle protein resulting from
chronic infection or glucocorticoid pharmacotherapy results in a
profound loss of muscle mass, functional impairment and mor-
tality (Figure 1). A defining feature of the cachexia syndrome,
this condition complicates, the vast majority of chronic diseases.
In addition to decreased quality of life, the presence of muscle
atrophy portends a negative outcome in numerous chronic dis-
eases (Tan et al., 2009; Noori et al., 2010; Fülster et al., 2013). It
is important to distinguish muscle atrophy from inflammatory
myopathy. The former involves a reduction in the size of muscle
fibers without disruption of the cell membrane, while in the latter
there is a marked immune cell infiltration into muscle and loss of
membrane integrity. This review will focus on the contribution
of glucocorticoid signaling to the pathogenesis of muscle atrophy
in chronic disease. Given the paucity of treatments for cachexia,
we will highlight current avenues of research with the potential to
offer therapeutic interventions in the future.
MOLECULAR MECHANISMS OF GLUCOCORTICOID-INDUCED
ATROPHY
INFLAMMATORY REGULATION OF THE HPA AXIS
Activation of the HPA axis by inflammation is a well-described
phenomenon with an extensive history of work. Through a
series of elegant studies, it was demonstrated that the proto-
typical cytokine interleukin-1β activates the HPA axis via the
regulation of CRH release without clear evidence for activity
at the level of the pituitary. The release of ACTH by pitu-
itary and subsequent release of corticosterone (the predomi-
nant glucocorticoid in rodents) by the adrenal gland is blocked
by immunoneutralization of CRH (Berkenbosch et al., 1987;
Sapolsky et al., 1987). Cytokines generated in the periphery
likely activate CRH neurons in a number of ways. A partic-
ularly well-characterized mechanism involves the induction of
FIGURE 1 | Glucocorticoids mediate a metabolic response to acute
and chronic inflammation. (1a) During acute infection, inflammatory
mediators act in the central nervous system activating hypothalamic CRH
neurons. (1b) Chronic inflammation, such as from tumor growth, also
activates hypothalamic CRH neurons. (2) The release of CRH into the
pituitary portal vasculature results in the release of ACTH by the anterior
pituitary into the systemic circulation. (3) ACTH acts on the adrenal gland,
resulting in the release of cortisol (or corticosterone in rodents). (4a)
Cortisol acts on skeletal muscle, resulting in the breakdown of contractile
protein and the mobilization of amino acids. (4b) Cortisol also acts on the
liver to increase hepatic gluconeogenesis. (5) The resultant substrate
mobilized from energy reserves serves to fuel the synthesis of acute
phase reactants as well as the innate and adaptive immune response. In
the case of acute infection, the resultant feedback loop results in
resolution and clearance of the offending organism, terminating the
inflammatory response and the mobilization of resources. However, in
cases of chronic inflammation such as cancer where the immune
response is unable to terminate the underlying inflammatory stimulus,
continuous mobilization of amino acids leads to a profound depletion of
skeletal muscle.
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cyclooxygenase in the cerebrovascular endothelium of the brain
stem, activating ascending projections that converge on CRH
neurons (Ericsson et al., 1995, 1997; García-Bueno et al., 2009).
Genetic inhibition of cytokine signaling in endothelium prevents
the activation of the HPA-axis by inflammatory cytokines (Ching
et al., 2007). Cytokines can also gain access to the CNS via areas
of permeable blood brain barrier known as circumventricular
organs, and act upon local neuronal populations that project to
hypothalamic CRH neurons (Buller, 2001). Finally, peripheral
inflammation can directly activate afferent projections originat-
ing in the periphery, thereby modulating HPA axis activation.
The vagus nerve expresses toll-like receptor 4 (TLR4), the cellu-
lar receptor for endotoxin, and vagotomy eliminates some of the
behavioral response to peripheral inflammation in certain mod-
els (Watkins et al., 1995). Other studies have demonstrated that
certain cytokines such as interleukin-6 and leukemia inhibitory
factor also exert a direct effect on the pituitary (Akita et al., 1995;
Bethin et al., 2000). Thus, a series of mechanisms that are differ-
entially evoked (based on the nature and site of the inflammatory
challenge), converge on the HPA axis, resulting in the release of
glucocorticoids.
GLUCOCORTICOIDS AS MEDIATORS OF ATROPHY
Glucucocorticoid-induced muscle atrophy was first noted in the
setting of Cushing’s Disease, were pituitary adenomas overpro-
duce ACTH (Cushing, 1994). It was not until the 1950’s that
metabolic tracing studies demonstrated the ability exogenously
administered glucocorticoids and ACTH to promote protein
degradation in muscle while simultaneously preventing protein
synthesis (Hoberman, 1950). Simultaneously, with increasing
pharmacologic use of glucocorticoids, came the recognition of
muscle atrophy as a side effect of glucocorticoid treatment in the
clinical entity steroid myopathy. However, the first evidence that
endogenous glucocorticoids contributed to the process of muscle
atrophy came in the observation that adrenalectomized animals
failed to undergomuscle atrophy in response to fasting (Wing and
Goldberg, 1993). Subsequent studies demonstrated an integral
role for endogenous glucocorticoids as fundamental mediators of
muscle atrophy in multiple conditions, as covered in detail in a
following section.
TISSUE SPECIFIC MODULATION OF GLUCOCORTICOID ACTIVITY BY
HYDROXYSTEROID DEHYDROGENASE ENZYMES
The activity of glucocorticoids in tissues is modulated by two
enzymatic activities that interconvert cortisol (corticosterone
in rodents) with its inactive metabolite cortisone (11-dehydro-
corticosterone in rodents). The enzyme 11-beta hydroxysteroid
dehydrogenase 1 (11β-HSD1) converts cortisone (that does not
bind the GR) to cortisol by hydrogenating the carbonyl oxy-
gen at the 11 position. It is expressed in numerous metabolic
tissues including liver, adipose tissue and brain. Additionally, it
is expressed in skeletal muscle where it plays an integral role
in the regulation of muscle atrophy. Cortisone is capable of
inducing proteolysis and atrophy in cultured myotubes, an effect
that is abolished in the presence of an inhibitor of 11β-HSD1
(Biedasek et al., 2011). Skeletal muscle 11β-HSD1 also modulates
glucocorticoid-induced insulin resistance, which as discussed
below, likely impacts atrophy (Morgan et al., 2009). 11β-HSD2
converts active cortisol into inactive cortisone, decreasing the
quantity of active glucocorticoid reaching the receptor. The best-
described physiologic role for 11β-HSD2 is in tissues respond-
ing to the mineralocorticoid aldosterone. Cortisol, despite being
the predominant circulating glucocorticoid in humans, binds to
the mineralocorticoid receptor with higher affinity than it does
to the GR. Therefore, in tissues such as the renal collecting
duct, 11β-HSD2 inactivates cortisol allowing mineralocorticoid
receptor signaling to be governed by circulating aldosterone con-
centrations (Chapman et al., 2013). The role (or indeed whether
it is expressed at all) of 11β-HSD2 in skeletal muscle is not
well described, and represents an exciting potential avenue for
investigation.
FIBER-TYPE SPECIFICITY OF GLUCOCORTICOID-INDUCED MUSCLE
ATROPHY
Glucocorticoids have a particular predilection for inducing the
atrophy of fast-twitch skeletal muscle, with slow twitch muscle
and to a greater extent cardiac muscle being largely protected
(Sandri et al., 2006; Shimizu et al., 2011). There is some teleo-
logic sense to this specificity, as fast twitch muscle may be more
expendable given the role of slow twitchmuscle inmaintenance of
posture and respiration. An apparent explanation for this discor-
dance in atrophy comes from the differential expression of the GR
between fiber types. While fast twitch muscles express abundant
GR, expression is relatively low in slow twitch muscles (Sandri
et al., 2006; Shimizu et al., 2011). An alternate explanation arises
from the expression of the transcriptional co-activator PGC-1α
in slow but not fast twitch fibers. Forced expression of PGC-1α
protects against fasting-induced atrophy by suppressing the tran-
scriptional activation of the atrophy program which is discussed
in detail below (Sandri et al., 2006).
DIRECT TRANSACTIVATION OF CATABOLIC REGULATORS
Within the context of the muscle cell, glucocorticoids induce
muscle atrophy through a variety of mechanisms. The GR is a
type I nuclear hormone receptor, and as such is localized to the
cytosol in the absence of ligand. However, upon ligand binding,
it translocates to the nucleus where interacts with specific DNA
sequences known as glucocorticoid response elements (GREs)
(recently reviewed in Kadmiel and Cidlowski, 2013). Once bound,
it assembles a complex of coactivators and mediators ultimately
resulting in the recruitment of RNA polymerase II and the ini-
tiation of transcription. An equally important mechanism by
which the ligand bound GRmediates gene transcription is via the
repression of other transcription factor complexes which occurs
independent of GR DNA binding. The best studied of these are
NF-κB and AP-1 which regulate an overlapping set of genes gov-
erning inflammation, growth and proliferation. Ligand bound
GR interferes with the binding of the p65 subunit of NF-κB to the
basal transcriptional machinery, preventing it from activating tar-
get inflammatory genes (De Bosscher et al., 2000). Similarly, the
GR interacts with c-Jun a component of the AP-1 complex, pre-
venting it from driving transcription of target genes (Wei et al.,
1998). Classically it has been believed that the metabolic effects
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of glucocorticoids are dependent on DNA binding and transcrip-
tional activation, while the anti-inflammatory effects depend on
DNA binding-independent repression. However, as is discussed
in detail below, recent work has called this mechanistic separation
into question.
MUSCLE-SPECIFIC UBIQUITIN LIGASES REGULATE ATROPHY
Early research into the molecular mechanisms of muscle atro-
phy focused on protein degradation, and which occurs largely
as the result of activation of the ubiquitin proteasome system
(UPS) (Although there has been renewed interest in the contri-
bution of the autophagy-lysosome system recently, as discussed
below). While many components of the UPS including pro-
teasomal subunits are increased in expression under atrophic
conditions, the regulators that mediate the specificity of this
reaction for myofibrillar protein remained elusive. Subsequent
screening efforts lead to the discovery of two E3 ubiquitin ligases
Muscle Atrophy F-box (MAFbx/atrogin-1) and Muscle Specific
Ring Finger Protein 1 (MuRF1) as being highly up-regulated
in muscle undergoing atrophy (Figure 2) (Bodine et al., 2001;
Gomes et al., 2001). Both are expressed exclusively in skeletal
muscle and requisite for the process of normal atrophy (Jagoe
et al., 2002; Lecker et al., 2004; Sacheck et al., 2007). MuRF1
directly participates in the ubiquitination and degradation of
heavy chain myosin and numerous heavy chain regulatory pro-
teins (Clarke et al., 2007; Cohen et al., 2009). In response to
dexamethasone treatment, MAFbx and MuRF1 play divergent
roles. MuRF1 knockout mice are resistant to dexamethasone-
induced muscle atrophy with preservation of muscle mass, fiber
cross sectional area and contractile properties (Baehr et al.,
2011). Interestingly, deletion of MAFbx does not protect against
muscle atrophy in response to glucocorticoid administration
despite the significant protection against denervation-induced
atrophy observed in MAFbx knockout mice (Bodine et al., 2001).
Furthermore, a distinct gene expression profile is observed in
MuRF1 knockout mice administered dexamethasone, including
alterations in genes involved with the neuromuscular junction
and fat metabolism (Furlow et al., 2013). This argues that MuRF1
also plays a critical role in regulating gene expression in atrophic
muscle.
FIGURE 2 | Cortisol and insulin signaling interact to modulate the
anabolic and catabolic balance in skeletal muscle. Cortisol and
corticosterone interact with cytosolic glucocorticoid receptor in skeletal
muscle. The majority of the effects of cortisol occur via glucocorticoid
receptor dimerization, nuclear localization and activation of transcription.
However, cytosolic ligand bound GR monomers also antagonize insulin
signaling at the level of PI3K. Nuclear GR induces the transcription of
multiple genes that partition into two distinct domains: Genes that
increase catabolic processes and genes that decrease anabolic
processes. Increased anabolic activity occurs via increased
ubiquitin-proteasome activity or increases in the activity of the
autophagy-lysosome system (not pictured). The reduction in anabolic
activity occurs via a number of pathways that converge to inhibit
mTOR-dependent protein translation. Insulin signaling opposes
glucocorticoid dependent mobilization of muscle protein via interaction
with membrane bound insulin receptor. Signaling downstream of the
insulin receptor results in inhibition of proteasomal targeting as well as
stimulating mTOR-dependent protein translation.
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In addition to regulating protein breakdown, both muscle spe-
cific E3 ligases also contribute to the decrease in protein synthesis
in response to glucocorticoid administration. Interestingly, the
principle role of MAFbx in muscle atrophy may be the regulation
of protein synthesis as, no MAFbx targets have been identified
that would allow it to directly participate in protein degrada-
tion. The only described substrates for this E3 ubiquitin ligase are
MyoD and eIF3-f controlling myogenic differentiation and pro-
tein translation respectively (Guttridge et al., 2000; Csibi et al.,
2009). Using a yeast two-hydrid screen, eIF3-f was identified as
a MAFbx interacting protein. In cultured myotubes subjected
to glucocorticoid treatment, MAFbx is rapidly upregulated with
a concurrent increase in ubiquitinated eIF3-f and a decrease in
total eIF3-f protein (Lagirand-Cantaloube et al., 2008). This is
dependent on multiple C-terminal lysine residues that serve as
the sites for polyubiquitination (Csibi et al., 2009). eIF3-f inter-
acts directly with the 40S ribosome and serves a critical function
in the formation of the pre initiation complex. Therefore, the
selective degradation of eIF3-f results in a global suppression of
translational initiation and subsequent protein synthesis. MuRF1
also mediates the suppression of protein synthesis in response
to glucocorticoid administration. MuRF1 knockout mice resist
the suppression of protein synthesis that occurs with dexametha-
sone administration, perhaps via the aforementioned regulation
of gene expression in muscle undergoing atrophy (Baehr et al.,
2011).
TRANSCRIPTIONAL REGULATION OF MUSCLE SPECIFIC E3 LIGASES
The upregulation of MAFbx and MuRF1 in response to gluco-
corticoid administration occurs as the result of the concerted
action of a series of transcription factors. A GRE is present in the
promoter region of the MuRF1 gene, and is responsive to glu-
cocorticoid administration (Waddell et al., 2008; Shimizu et al.,
2011). However, no GRE has been identified in the MAFbx pro-
moter demonstrating that additional transcription factors are
requisite for initiation of the atrophy program. The Forkhead-
box (Foxo) family of transcription factors plays a critical role
in regulating muscle atrophy (Sandri et al., 2004). The activity
of this transcription factor family is regulated via both tran-
scriptional and post-translational mechanisms. Upstream growth
factors such as insulin and IGF-1 (detailed below) inhibit Foxo
activity via a signal transduction pathway culminating in Foxo
phosphorylation and nuclear exclusion. Additionally, Foxo tran-
scription factors are upregulated at the gene expression level in
response to glucocorticoid treatment (Lecker et al., 2004; Braun
et al., 2011). A putative GRE has been identified in the Foxo3a
promoter, although the activity of this site in muscle has yet to
be confirmed (Lützner et al., 2012). Transgenic overexpression
of Foxo1 in skeletal muscle is sufficient to drive muscle atro-
phy, arguing that both Foxo phosphorylation and total expression
level govern the activity of these transcription factors. Foxo tran-
scription factors increase the transcription of the muscle-specific
E3 ligases via binding to conserved elements in the promoter
and the assembly of the transcriptional apparatus. The MAFbx
promoter contains Foxo binding sites that are required for acti-
vation of MAFbx expression (Sandri et al., 2004). The GRE and
Foxo binding elements in the MuRF1 promoter are close in
proximity and interact synergistically to induce MuRF1 expres-
sion in response to glucocorticoid treatment (Waddell et al.,
2008).
Glucocorticoids also regulate the expression of MAFbx and
MuRF1 via a transcription factor known as Krüppel-like factor
15 (KLF15) (Shimizu et al., 2011). Ligand bound GR induces the
transcription of KLF15, which subsequently interacts with the
promoter regions of both MAFbx and MURF1 to induce their
expression. Furthermore, overexpression of constitutively active
forms of both transcription factors results in additive increases
in MAFbx and MuRF1 promoter activity and expression. KLF15
overexpression also results in increased expression of Foxo1 and
Foxo3a, demonstrating further crosstalk between these transcrip-
tion factors. It is the synergistic interplay between ligand bound
glucocorticoids and this induced transcription factor network
that regulates muscle mass via the activation of MAFbx and
MuRF1.
It has recently come to light that glucocorticoids may also
activate inflammatory signaling pathways asmechanism of induc-
ing atrophy. The adaptor protein TRAF6 is classically thought
to couple inflammatory signals from membrane bound cytokine
receptors to down-stream transcription factor networks inducing
the inflammatory response such as NF-κB. However, pharmaco-
logic doses of dexamethasone increase TRAF6 expression, and
TRAF6 knockdown attenuates dexamethasone-induced atrophy
both in vitro and in vivo (Sun et al., 2014). The demonstration that
glucocorticoid signaling activates inflammatory pathways argues
against the exclusively anti-inflammatory role of glucocorticoids.
Further, it brings clarity to previously disparate data demon-
strating that both glucocorticoids and NF-κB are necessary and
sufficient for inflammatory muscle atrophy by suggesting they act
in the same pathway (Cai et al., 2004; Braun and Marks, 2010;
Braun et al., 2013).
AUTOPHAGY AS A MECHANISM OF PROTEIN BREAKDOWN IN
SKELETAL MUSCLE
Autophagocytic digestion of contractile proteins and organelles
also plays a critical role in the process of muscle atrophy, and
shares similar regulatory machinery [For a full discussion of
autophagy and muscle atrophy, see the following recent review
(Sandri, 2010)]. Foxo3 induces the expression of Bnip3, LC3
and Gabarapl1 in skeletal muscle undergoing atrophy, lead-
ing to increased autophagosome assembly and lysosomal fusion
(Mammucari et al., 2007). Foxo3a directly regulates LC3 gene
expression by interacting with Foxo binding elements in its pro-
moter. Interestingly, mitochondrial autophagy (mitophagy) was
recently identified as a contributor to muscle atrophy, with the
E3 ubiquitin ligase Mul1 playing a fundamental regulatory role
(Lokireddy et al., 2012). The treatment of culturedmyotubes with
dexamethasone induces Mul1 expression and induces mitophagy.
Foxo transcription factors also regulate mitophagy via interac-
tion with the Mul1 promoter and regulation of expression. A
complete description of the role of autophagy in muscle atro-
phy is beyond the scope of this review. However, it is clear that
autophagy plays an important role inmediating the breakdown of
protein in response to glucocorticoid treatment, acting in concert
with the ubiquitin proteasome system.
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GLUCOCORTICOID-MEDIATED INHIBITION OF ANABOLIC PATHWAYS
Although there was initially more interest in catabolic path-
ways in skeletal muscle, there has been renewed interest in
understanding the suppression of protein synthesis as a mech-
anism of muscle atrophy. A central player in the regulation of
global protein synthesis is the mammalian target of rapamycin
(mTOR) complex. The activity of the mTOR is regulated by
the TSC1/2 complex, which functions as a GTPase-activating
protein (GAP) for Rheb. (The basic mechanisms of mTOR sig-
naling have been recently reviewed in Laplante and Sabatini,
2012). GTP-bound Rheb stimulates mTOR activity, while GDP-
Rheb inhibits it. Thus, assembly of the TSC1/2 complex increases
GDP-Rheb, inhibiting mTOR activity. Regulated in Development
and DNA Damage Responses (REDD1) is significantly upregu-
lated in response to glucocorticoid administration and has been
identified as a direct glucocorticoid-target gene by several stud-
ies (Shimizu et al., 2011; Kuo et al., 2012). Under catabolic
conditions, REDD1 promotes the assembly of the TSC1/2 com-
plex, inhibiting mTOR and protein synthesis (Wang et al.,
2006). Likewise, sestrin1 is also a glucocorticoid target gene that
serves to inhibit mTOR signaling by increasing the activity of
the TSC1/2 complex (Budanov and Karin, 2008; Braun et al.,
2011; Kuo et al., 2012). Sestrin1 activates AMP-responsive pro-
tein kinase (AMPK), which phosphorylates Tsc2, increasing its
GAP activity and thereby suppressing mTOR. In addition to
its catabolic function, KLF15 also possesses anti-anabolic activ-
ity, which it achieves via regulation of the mammalian target of
rapamycin (mTOR) complex (Shimizu et al., 2011). Branched
chain amino transferase 2 (BCAT2) is a mitochondrial enzyme
that catalyzes the initial step in branched chain amino acid
(BCAA) degradation and is transcriptionally regulated by KLF15.
BCAAs stimulate the activity of mTOR, increasing translational
initiation. The fall in BCAA levels in response to glucocor-
ticoid signaling inhibits mTOR, subsequently decreasing pro-
tein synthesis. Indeed, supplementation with BCAAs improves
mTOR activation and attenuates muscle atrophy in response
to treatment with glucocorticoids (Shimizu et al., 2011). The
regulation of protein synthesis by mTOR does not occur in
isolation, as supplementation of BCAAs not only suppresses
dexamethasone-induced mTOR inhibition, but also prevents the
induction of MAFbx and MuRF1. Therefore, it is clear that
glucocorticoids exert a significant component of their catabolic
effect via inhibition of mTOR signaling. However, significant
cross-talk between protein degradation and synthesis occur such
that the two are coupled to avoid futile cycling of amino
acids.
GENERATION OF OXIDATIVE STRESS
The generation of reactive oxygen species within catabolic muscle
is also a significant driver of atrophy in response to inflamma-
tion or disuse (Li et al., 2005; Suzuki et al., 2007) and antioxidant
administration attenuates muscle atrophy in response to LPS
administration (Jin and Li, 2007). Oxidative stress produces atro-
phy principally via activation of p38 mitogen activated protein
kinase (MAPK), which subsequently induces the expression of
MAFbx, MuRF1 as well as the autophagy-lysosome system (Li
et al., 2005; McClung et al., 2010; Doyle et al., 2011). While few
studies exist demonstrating that glucocorticoids induce oxida-
tive stress in skeletal muscle, there is an extensive literature
documenting this process in other tissues (You et al., 2009;
Almeida et al., 2011). It is therefore tempting to speculate that
glucocorticoids may also induce atrophy via the generation of
oxidative stress in muscle. This potential mechanism of glucocor-
ticoid action on muscle represents and exciting avenue for future
investigation.
MYOSTATIN
Myostatin is a small secreted protein produced in skeletal muscle
that inhibits muscle growth (McPherron et al., 1997). Myostatin
signals via the type II activin receptor, leading to the phospho-
rylation of the transcription factors SMAD2 and SMAD3 (Lee
and McPherron, 2001; Rebbapragada et al., 2003). Through the
action of these transcription factors, myostatin down regulates
numerous genes involved in myogenic differentiation such as
MyoD, myogenin and myf5 (Langley et al., 2002; McFarlane et al.,
2006). Myostatin signaling is implicated as a crucial intermediary
between glucocorticoid signaling and muscle atrophy. Putative
GREs are present in the human myostatin promoter (Ma et al.,
2001). Consistent with this, glucocorticoids upregulate myostatin
expression, and increase myostatin promoter activity (Allen and
Loh, 2011). Furthermore, myostatin knockout mice fail to exhibit
any muscle atrophy in response to glucocorticoid administration
(Gilson et al., 2007). Critically, it was recently demonstrated that
treatment of cancer cachexia in mice by the administration of a
soluble type II activin receptor, improves survival independent
from cancer progression (Zhou et al., 2010).
REGULATION OF INSULIN SIGNALING
It has long been appreciated that insulin and glucocorticoid sig-
naling exert reciprocal forces on skeletal muscle mass. It has
recently become clear however that rather than exerting this con-
trol via opposing, independent mechanisms, glucocorticoids fun-
damentally alter the transduction of signals downstream from the
insulin receptor. Upon binding to their cognate receptors, IGF1
and insulin stimulate the recruitment of the insulin-receptor sub-
strate -1 (IRS-1). After recruitment, IRS-1 is phosphorylated by
the kinase activity of the insulin receptor, and serves as a docking
site for PI3K. A recent genome wide analysis of GR binding iden-
tified p85α as a direct GR target gene (Kuo et al., 2012). Encoding
the regulatory subunit of phosphatidylinositol 3- kinase (PI3K),
p85α modulates insulin signaling via the relative abundance of
inhibitory homodimers and active PI3K formed from p85α/p110
heterodimers. As such, overexpression of p85α under the influ-
ence of glucocorticoids, tips this balance in favor PI3K inhibition,
resulting in decreased activation of the downstream kinase Akt.
Of the many targets of Akt, perhaps the most important with
regard to muscle atrophy are the Foxo transcription factors,
which are excluded from the nucleus when phosphorylated by
Akt, preventing them from transactivating the muscle-specific
E3 ligases (Sandri et al., 2004). The glucocorticoid receptor also
exerts DNA-binding independent effects on insulin signaling via
direct interaction with PI3K (Hu et al., 2009). The effect of this
interaction is to sequester PI3K subunits away from upstream
signaling proteins in the insulin-receptor signaling cascade,
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preventing PI3K activation, leading eventually to Foxo1 nuclear
localization.
MicroRNAs AS MEDIATORS OF GLUCOCORTICOID-INDUCED MUSCLE
ATROPHY
MicroRNAs (miRNAs) are small ∼22 nucleotide RNAs that sup-
press mRNA expression via translational suppression and mRNA
decay. Over the last decade, miRNAs have been shown to play
a role in a diverse array of biological processes. Muscle is no
exception to this, as recent reports have implicated miRNAs in
the process of atrophy. In response to glucocorticoid treatment,
miR-1, miR-147, miR-322, miR-351, and miR-503, miR-708 are
found at increased levels in muscle cells (Shen et al., 2013).
While the precise roles of many of these induced miRNAs has
not been elucidated, the effect of miR-1 has been well character-
ized. One of the principle targets of miR-1 muscle is heat shock
protein 70 (HSP70), which decreases in expression in response to
glucocorticoid treatment (Kukreti et al., 2013). HSP70 binds to
phosphorylated Akt, protecting it from dephosphorylation, and
maintaining Foxo transcription factors in their phosphorylated,
inactive state. The miR-1 mediated loss of HSP70 expression in
response to glucocorticoid administration results in the inac-
tivation of Akt signaling with subsequent nuclear localization
of Foxo1 and induction of MAFbx and MuRF1. Other miRNA
species appear to play a protective role against atrophy. miR-
23a directly interacts with MAFbx and MuRF1 mRNA, inhibiting
their expression and therefore the induction of muscle atrophy
(Wada et al., 2011). Likewise, miR-27a and b also serve to inhibit
muscle atrophy. Both of these miRNA species interact with the
3′ UTR of myostatin mRNA, decreasing its stability and half-life
(Allen and Loh, 2011). In response to dexamethasone treatment,
the levels of both miR27a and b decrease in skeletal muscle, facili-
tating an increase in myostatin expression, contributing tomuscle
atrophy. The role of miRNAs as mediators of muscle atrophy
is a relatively nascent field with a great deal of that is as-of-yet
unkown. However, early results suggest that they serve important
roles as positive and negative regulators of muscle atrophy both
via interaction with signaling pathways and by direct inhibition
of catabolic mediators. Further dissection of the role of miRNAs
in muscle atrophy will likely superimpose a new layer of com-
plexity onto the transcriptional and translational regulation of
glucocorticoid-induced muscle atrophy.
GLUCOCORTICOID REGULATION OF MUSCLE SATELLITE CELLS
Increasingly, it is becoming appreciated that satellite cells, the res-
ident stem cell population within skeletal muscle, play a critical
role in the pathogenesis of muscle atrophy. In response to can-
cer growth, satellite cells are activated and enter the cell cycle (He
et al., 2013). However, their fusion with the mature myofiber is
impaired due to upregulation of the transcription factor Pax7.
This appears to be dependent upon a circulating factor that is
small and not susceptible to heat-inactivation. A second recent
report demonstrates that synthetic glucocorticoids are potent
inhibitors of satellite cell function (Dong et al., 2013). As gluco-
corticoids have recently been implicated in the pathogenesis of
cancer cachexia, this provides a testable mechanism for satellite
cell dysfunction in cancer (Braun et al., 2013).
GLUCOCORTICOIDS IN DISEASE
INFLAMMATORY CYTOKINES, ENDOTOXEMIA AND SEPSIS
With the development of techniques for the production of recom-
binant cytokines, there was extensive interest in understanding
the mechanisms by which they elicit muscle protein breakdown.
These studies utilized an in vivo inflammatory challenge fol-
lowed by the measurement of tyrosine release from an explanted
muscle into culture media. Initial studies in which recombinant
cytokines were given to animals in the presence of the GR antag-
onist mifepristone produced mixed results (Zamir et al., 1992).
Administration of the glucocorticoid antagonist mifepristone
attenuates the induction of muscle protein degradation brought
about by tumor necrosis factor (TNF). In contrast, the proteolysis
accompanied by interleukin-1 α administration was not blocked
by concurrent mifepristone. However, the interpretation of these
studies was complicated by mortality approaching 50% with con-
current cytokine andmifepristone administration, likely speaking
to the necessity of glucocorticoid signaling for maintaining car-
diovascular stability in the face of inflammatory challenge. When
inflammatory cytokines are delivered directly into the brain,
a rapid induction of MAFbx, MuRF1, and Foxo1 is observed
in muscle and this induction is blocked by adrenalectomy or
mifepristone administration (Braun et al., 2011). Additionally,
the induction of these genes 8 h after peripheral lipopolysac-
charide (LPS) administration is also blocked by adrenalectomy.
However, other cytokine systems may produce muscle atrophy
independent from the action of glucocorticoids. The TWEAK-
Fn14 system potently induces muscle atrophy (Mittal et al.,
2010). High doses of glucocorticoids fail to induce the TWEAK-
Fn14 system. Further, it has yet to be investigated whether, like
other inflammatory cytokines, glucocorticoid antagonism pre-
vents TWEAK-induced muscle atrophy.
The role of glucocorticoids in muscle atrophy seen in exper-
imental sepsis has also been investigated using a rodent cecal
ligation and puncture (CLP) model. In juvenile rats, mifepris-
tone significantly reduced tyrosine release from muscle explants
harvested 16 h after CLP, arguing for glucocorticoids as a funda-
mental driver of this process (Tiao et al., 1996). Subsequent work
demonstrated that the E3 ligases MAFbx andMuRF1 are also reg-
ulated by glucocorticoids in the juvenile CLP model (Wray et al.,
2003). Contrasting results emerged from a CLP model in adult
rats, where mifepristone failed to alter the induction of MAFbx
and MuRF1 in septic rats despite effectively blocking the induc-
tion of these genes by dexamethasone at a similar time point
(Frost et al., 2007). Although an explanation for these disparate
results is not immediately apparent, it may reside in the relatively
short 1–2 h half-life of mifepristone rodents (Heikinheimo et al.,
1994). These studies examined gene expression at different time
points (16 h after CLP in juvenile rats vs. 24 h in adults), a period
of 4–8 half lives. It is further possible that sepsis significantly alters
this half-life, rendering the drug effective at 16 h and not at 24 h.
Continued work in the juvenile CLP model has demonstrated a
significant induction of Foxo1 expression with PPARβ/δ playing a
critical upstream role (Castillero et al., 2013).
A major limitation to this line of investigation has been the
relatively blunt tools available for blocking glucocorticoid activ-
ity. Mifepristone has activity at other steroid receptors, and its use
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is limited by a very short half-life. Adrenalectomy can be used
effectively at short time points after the induction of inflamma-
tion, however these animals are 1000-fold more susceptible to the
lethal effects of inflammatory challenges, precluding the investi-
gation of longer time points (Masferrer et al., 1992). Therefore,
studies using mouse genetics to specifically interrogate the role
of glucocorticoid signaling in skeletal muscle have clarified this
question (Braun et al., 2013). Mice harboring a muscle-specific
deletion of the GR display a significantly attenuated induction of
MAFbx and MuRF1 in response to LPS administration. Further,
given that glucocorticoid signaling is intact in other tissues in
these animals, longer time points could be assessed after inflam-
matory challenge. In these experiments, the deletion of the GR
in skeletal muscle largely prevents muscle mass loss or the loss
of fiber cross sectional area in response to LPS administration.
In total these results demonstrate the integral role for gluco-
corticoid signaling in muscle atrophy in the setting of acute
inflammation.
DIABETES
Acute diabetes arising from insulin deficiency has long been
appreciated to produce glucocorticoid-dependent muscle atro-
phy. Adrenalectomized mice resist muscle atrophy in response
to streptozotocin-induced diabetes (Hu et al., 2009). However,
when the synthetic glucocorticoid dexamethasone is given in iso-
lation at a dose estimated to mimic endogenous concentrations
in diabetic animals, it is insufficient to evoke substantial atro-
phy. However, this same dose of dexamethasone restores normal
muscle atrophy when administered to diabetic adrenalectomized
mice. Through a series of elegant studies, it was demonstrated
that the combined lack of anabolic insulin signaling and gluco-
corticoid signaling are necessary to produce atrophy in response
to diabetes.
RENAL FAILURE AND METABOLIC ACIDOSIS
One of the hallmarks of chronic kidney disease (CKD) is
a metabolic acidosis due to impaired renal acid excretion.
Metabolic acidosis, like diabetes, was among the early conditions
in which the elevated rate of muscle protein degradation was
attributed to glucocorticoids. In these studies, animals subjected
to experimental chronic acidosis demonstrated a significant
increase in the rates of skeletal muscle protein degradation, which
was prevented by adrenalectomy (May et al., 1986). Increased
angiotensin II levels are also found in CKD, and implicated
in the pathogenesis of muscle wasting in this condition. When
angiotensin II is infused at concentrations mimicking endoge-
nous production in CKD, significant muscle wasting occurs that
is reversed by co-administration of the glucocorticoid antagonist
mifepristone (Song et al., 2005). As of yet, there have been no
studies directly assessing the contribution of glucocorticoids to
muscle wasting in an experimental model of chronic kidney dis-
ease. However, in such models, urinary glucocorticoid excretion
is elevated (May et al., 1987), with serum levels likely elevated
into a range known to produce wasting in isolation. Therefore,
with the advent of genetic models to investigate the impact of
glucocorticoid signaling on skeletal muscle, such results are likely
forthcoming.
CANCER
Tumor growth is associated with a significant increase in systemic
inflammation and elevated levels of circulating glucocorticoids.
Therefore, it was surprising when initial studies using glucocorti-
coid antagonists or adrenalectomy failed to improve muscle mass
in tumor bearing animals (Tessitore et al., 1994; Llovera et al.,
1996; Rivadeneira et al., 1999). As a result, it was concluded that
endogenous glucocorticoids do not contribute to muscle wast-
ing in cancer, and a mechanism involving the direct action of
cytokines on skeletal muscle came into favor. Recent work with
muscle-specific GR knockout mice has returned the glucocorti-
coid hypothesis of cancer cachexia to the forefront. When the
GR is deleted from skeletal muscle, muscle wasting in response
to tumor growth is blocked (Braun et al., 2013). The discrep-
ancy between these findings likely arises from the systemic effects
of glucocorticoid signaling that are integral to the response to
stressful stimuli and blocked in the setting of adrenalectomy or
systemic antagonist administration. In addition, mifepristone has
a very short half life in rodents on the order of 1–2 h, and there-
fore may be more appropriate for the investigation of acute events
rather than chronic effects taking place over the course of weeks
(Heikinheimo et al., 1994). Alternately, it is possible that some
tumor models produce a glucocorticoid-dependent muscle wast-
ing, while others do not, as different models were utilized in these
studies. Future studies will likely expand upon the dependence of
cancer cachexia on glucocorticoids and explore the applicability
of these findings to the human condition.
DIRECTION OF FUTURE WORK
Given the nodal nature of glucocorticoids as a regulator of mus-
cle mass in chronic disease, there are a number of exciting
avenues of research for future investigation. Principal among
these is the development of a more refined understanding of
the precise mechanisms of glucocorticoid-induced atrophy. Given
the rapidly expanding field of non-genomic effects of steroid
hormone receptors, future work will likely explore the inter-
play between the genomic targets of the GR and its non-
genomic interaction with crucial signaling pathways. A second
and equally interesting area of investigation will be resolving the
apparent paradox for the requirement of glucocorticoid signal-
ing as well as inflammatory signaling pathways it is known to
inhibit. It will be interesting to discover whether there is synergy
between NFκB and glucocorticoid signaling with regard to skele-
tal muscle atrophy and the precise molecular mechanisms of this
effect.
A long-standing goal in glucocorticoid research is the devel-
opment of novel GR agonists that serve as effective anti-
inflammatory agents but have a reduced side effect profile. Given
the extensive use of glucocorticoids as anti-inflammatory agents,
and the significant toxicity associated with their use, any agent
with an improved therapeutic index would be of significant
clinical use.
The blockade of the catabolic effects of endogenous glucocorti-
coids is perhaps a taller order. The pleotropic effects of glucocor-
ticoids on nearly every organ makes glucocorticoid antagonism
a therapeutic approach encumbered by significant potential side
effects. The ideal agent would displace cortisol from the GR
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in muscle, preventing catabolism while simultaneously allowing
normal signaling in other tissues.
An interesting feature of glucocorticoid-induced muscle
atrophy is that transcriptional activation dominates over
transcriptional repression. It has been proposed that the anti-
inflammatory and metabolic effects of glucocorticoid signaling
can be separated on the basis transrepression and transactiva-
tion respectively. This concept originated with the finding that
point mutations in the GR dimerization loop prevented dimer-
ization and subsequent transcriptional activation of canonical
glucocorticoid response elements, while maintaining the ability
to transrepress NFκB and AP-1 dependent reporter constructs
(Reichardt et al., 2001). Mice with the targeted A458T point
mutation (GRdim) in the dimerization loop are viable in contrast
to the perinatal lethality observed in the GR knockout mouse
(Reichardt et al., 1998). Initial studies in these mice were very
promising, as dexamethasone administration continued to sup-
press PMA-induced skin inflammation but failed to alter the
expression of genes regulating carbohydrate balance (Reichardt
et al., 1998; Tuckermann et al., 1999). The initial elegance of
this model in which negative and positive effects are neatly par-
titioned into transactivation and transrepression respectively has
unfortunately not born out. A study documenting the transcrip-
tional response to prednisolone in GRdim mice revealed marked
variability with a subset of genes demonstrating an exagger-
ated response relative to wild type mice (Frijters et al., 2010).
When GRdim mice are treated with dexamethasone, there is a
significant attenuation of weight loss compared with wild type
mice (Waddell et al., 2008). In concordance with this, the induc-
tion of MuRF1 and Foxo1 in skeletal muscle by dexamethasone
is markedly attenuated. However, GRdim exhibit an equivalent
degree of muscle atrophy, arguing against the hypothesis that
dimerization dependent-transactivation is the sole mechanism
for muscle atrophy. The concept that the anti-inflammatory
action of glucocorticoids is dependent on transrepression has
also recently been challenged. A large component of the anti-
inflammatory action of glucocorticoids occurs as the result of
transcriptional activation of the gene dual specificity phosphatase
1 (Dusp1) rather than the transrepression of NFκB and AP-1
(Hammer et al., 2006; Vandevyver et al., 2012). Mice harboring a
deletion of Dusp1 demonstrate increased sensitivity to the lethal
effects of LPS administration as a result of excess inflammatory
cytokine production.
The emergent complexity glucocorticoid signaling makes the
rational development of GR ligands with the ability to block the
catabolism of muscle difficult. It is clear that a model in which
desirable and non-desirable effects can be dissociated on the basis
of GR dimerization does not accurately reflect the biology of glu-
cocorticoids. Despite this, many new ligands of the GR, termed
selective GR modifiers (SGRMs) have been developed, each with
its own unique gene activation and repression profile. While such
compounds have yet to be characterized in skeletal muscle, there
is reason to be hopeful that via the careful combination of in vitro
and in vivo screening, anti-catabolic GR ligands will be identified.
Given the growing evidence for the central role of glucocorticoids
as mediators of muscle atrophy, and the clinical burden of wasting
disorders, the need for further research on such agents is high.
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